PharmTech Drug Digest 11.20
|Articles|May 8, 2014

FDA Approves Omega-3 Therapy for High Triglycerides

Author(s)Melanie Sena

AstraZeneca's Epanova is the first FDA-approved prescription omega-3 in free fatty acid form.

The FDA has approved AstraZeneca’s Epanova, (omega-3-carboxylic acids) a treatment to help reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL). Epanova is the first FDA-approved prescription omega-3 in free fatty acid form.

The FDA approval was based on data from a clinical development program that included positive results from the Phase III trial, which examined the efficacy of Epanova in lowering triglycerides and other key lipid parameters in patients with high triglycerides. The effect of Epanova on the risk of pancreatitis or on cardiovascular mortality and morbidity has not been determined.

AstraZeneca continues to assess the impact of lowering triglycerides and further evaluate the clinical profile of Epanova. Through a large-scale trial, AstraZeneca will evaluate the safety and efficacy of Epanova on cardiovascular outcomes in combination with statin therapy in patients with mixed dyslipidemia at increased risk of cardiovascular disease. The company also plans to pursue the development of a fixed dose combination of Epanova with a statin and plans to file for regulatory approval in other markets for the severe hypertriglyceridemia indication.

Source: AstraZeneca


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.